

# NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

## Multiple Technology Evaluation

### Equality impact assessment – Scoping

#### Ivacaftor–tezacaftor–elexacaftor, tezacaftor–ivacaftor and lumacaftor–ivacaftor for treating cystic fibrosis [ID3834]

The impact on equality has been assessed during this evaluation according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

The following points were raised during the consultation:

- At present the draft scope and remit does not acknowledge the comprehensive nature of the interim access agreement, particularly for those people accessing modulator therapies under licensing decisions by the U.S FDA. Without inclusion in this appraisal, the recommendations could lead to a different impact for this community and make it more difficult for this specific group to access the technologies in practice. Access may be dependent on via individual funding requests (IFRs) which could lead to variation across the UK and could cause adverse effects if this community of people with cystic fibrosis cannot access these transformative treatments.
- It should be noted that people without a F508 del mutation make up a higher-proportion of the non-white population with CF.
- The incidence of F508del varies between different populations, being most high in Northern European countries.
- By restricting this HTA to people with one or two F508del, there is a risk of discriminating against ethnic groups with lower frequency of this variant.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

Issues of differences in disease prevalence cannot be addressed in a technology appraisal. The committee will consider carefully if its recommendations make access to elexacaftor, tezacaftor, lumacaftor and ivacaftor more difficult for certain groups.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

No.

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the stakeholder list been made?

No additional stakeholders related to potential equality issues were identified during the scoping process.

**Approved by Associate Director (name):** Linda Landells

**Date:** 18 January 2023